Latest News for: stromal

Edit

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

PR Newswire 18 Mar 2025
(NASDAQ. HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST) ... HT-KIT ... Next Steps in Development ... S.
Edit

Gastrointestinal Stromal Tumors Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 06 Mar 2025
DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.
  • 1
×